Requires labeling of over-the-counter and prescription drugs containing major food allergen or gluten-containing grain.
Impact
If enacted, A3131 would amend existing state food and drug laws to include specific labeling requirements for drugs, thus helping to prevent misbranding. It introduces penalties for violations, including fines for non-compliance based on the number of offenses. The responsibility for enforcement falls to the Department of Health, which is tasked with ensuring compliance with these new labeling rules. This could significantly affect manufacturers and distributors of medications, who will need to adapt their labeling practices to align with the new regulations.
Summary
Assembly Bill A3131 seeks to enhance consumer safety by requiring clear labeling on over-the-counter and prescription drugs that contain ingredients derived from major food allergens or gluten-containing grains. The bill mandates that such drugs bear labels indicating the presence of these ingredients, specifying the specific type of gluten-containing grain when applicable. This initiative is intended to help individuals with allergies and gluten sensitivities make informed decisions regarding their medication, enabling them to avoid adverse health reactions.
Contention
There may be notable points of contention regarding A3131, primarily related to the impact on the pharmaceutical industry and potential costs associated with updating labels and compliance measures. Some stakeholders may argue that the bill adds unnecessary regulatory burdens on drug manufacturers, while proponents emphasize the importance of protecting consumers who are at risk from allergens. As with many health and safety-related regulations, discussions surrounding this bill may involve balancing consumer protection with the operational realities within the pharmaceutical sector.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.